PL2908865T3 - Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka - Google Patents

Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka

Info

Publication number
PL2908865T3
PL2908865T3 PL13847711T PL13847711T PL2908865T3 PL 2908865 T3 PL2908865 T3 PL 2908865T3 PL 13847711 T PL13847711 T PL 13847711T PL 13847711 T PL13847711 T PL 13847711T PL 2908865 T3 PL2908865 T3 PL 2908865T3
Authority
PL
Poland
Prior art keywords
chimera
fas
cancer treatment
treatment methods
adenovirus expressing
Prior art date
Application number
PL13847711T
Other languages
English (en)
Inventor
Eyal Breitbart
Andrea LEUBITZ
Erez Feige
Richard PENSON
Original Assignee
Vascular Biogenics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd. filed Critical Vascular Biogenics Ltd.
Publication of PL2908865T3 publication Critical patent/PL2908865T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13847711T 2012-10-17 2013-10-17 Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka PL2908865T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261715206P 2012-10-17 2012-10-17
US201361785287P 2013-03-14 2013-03-14
PCT/IB2013/003015 WO2014060848A2 (en) 2012-10-17 2013-10-17 Treatment methods using adenovirus
EP13847711.2A EP2908865B1 (en) 2012-10-17 2013-10-17 Adenovirus expressing a fas-chimera and use thereof in cancer treatment methods

Publications (1)

Publication Number Publication Date
PL2908865T3 true PL2908865T3 (pl) 2019-08-30

Family

ID=50488836

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13847711T PL2908865T3 (pl) 2012-10-17 2013-10-17 Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka

Country Status (25)

Country Link
US (4) US9200056B2 (pl)
EP (2) EP3441089B1 (pl)
JP (2) JP6336459B2 (pl)
KR (2) KR102229084B1 (pl)
CN (2) CN105025931B (pl)
AU (3) AU2013333571B2 (pl)
BR (1) BR112015008612A2 (pl)
CA (1) CA2888193A1 (pl)
CY (1) CY1121185T1 (pl)
DK (1) DK2908865T3 (pl)
EA (1) EA034163B1 (pl)
ES (1) ES2703913T3 (pl)
HR (1) HRP20182125T1 (pl)
HU (1) HUE042262T2 (pl)
IL (2) IL238313B (pl)
LT (1) LT2908865T (pl)
MX (2) MX366163B (pl)
NZ (1) NZ707336A (pl)
PL (1) PL2908865T3 (pl)
PT (1) PT2908865T (pl)
RS (1) RS58122B1 (pl)
SG (2) SG10201706485WA (pl)
SI (1) SI2908865T1 (pl)
WO (1) WO2014060848A2 (pl)
ZA (1) ZA201502712B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
PL2908865T3 (pl) 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
DK3127545T3 (da) * 2014-04-04 2020-08-10 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer
ES2796857T3 (es) * 2014-04-17 2020-11-30 Inst Nat Sante Rech Med Polipéptidos y usos de los mismos para reducir la motilidad celular mediada por CD95
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
CA3048313A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
JP2021500355A (ja) * 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド 抗血管新生薬剤療法のための診断方法
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
KR20210139329A (ko) * 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 항종양 요법의 방법
MX2021012398A (es) * 2019-04-12 2021-11-12 Vascular Biogenics Ltd Metodos de terapia antitumoral.
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof
WO2023043632A1 (en) * 2021-09-16 2023-03-23 Corcept Therapeutics Incorporated Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
UA70909C2 (uk) 1993-10-25 2004-11-15 Канджи Інк. Рекомбінантний аденовірусний вектор, фармацевтична композиція, що його містить, та набір для зменшення проліферації пухлинних клітин
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
CN1294268C (zh) 2001-09-03 2007-01-10 上海三维生物技术有限公司 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
KR20070044868A (ko) 2005-10-26 2007-05-02 주식회사 바이오인프라 스트렙토라이신 ｏ 단백질을 암호화하는 유전자를 발현하는재조합 아데노바이러스 및 이를 유효성분으로 하는 항암용조성물
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
EP2128261B1 (en) 2006-12-20 2012-06-06 Shenzhen Chingen Genetic Engineering Co., Ltd. A recombinant adenovirus comprising recombinant khp53 gene and preparation method and uses thereof
CN101348512B (zh) 2007-07-20 2012-08-15 郑州威瑞生物技术有限公司 一种抗肿瘤的腺病毒制剂
JP4896102B2 (ja) 2008-09-12 2012-03-14 富士フイルム株式会社 レンズ装置
KR101248912B1 (ko) 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
AU2011204407B2 (en) * 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
JP6009357B2 (ja) 2010-01-12 2016-10-19 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
KR101253276B1 (ko) 2010-07-27 2013-04-10 윤채옥 복합 유전자 치료용 항종양 조성물
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
WO2012052423A1 (en) 2010-10-18 2012-04-26 Total Petrochemicals Research Feluy Expandable vinyl aromatic polymers
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent

Also Published As

Publication number Publication date
SI2908865T1 (sl) 2019-02-28
BR112015008612A2 (pt) 2017-09-26
US11311583B2 (en) 2022-04-26
EA201590747A1 (ru) 2015-10-30
MX366163B (es) 2019-07-01
HUE042262T2 (hu) 2019-06-28
HK1208625A1 (en) 2016-03-11
PT2908865T (pt) 2019-01-11
JP6630397B2 (ja) 2020-01-15
WO2014060848A2 (en) 2014-04-24
KR102229084B1 (ko) 2021-03-18
EP2908865A4 (en) 2016-05-25
RS58122B1 (sr) 2019-02-28
ES2703913T3 (es) 2019-03-13
AU2013333571A1 (en) 2015-05-14
IL238313A0 (en) 2015-06-30
EP2908865B1 (en) 2018-10-03
CA2888193A1 (en) 2014-04-24
CN105025931A (zh) 2015-11-04
AU2018271398A1 (en) 2018-12-20
ZA201502712B (en) 2016-07-27
CN107096041A (zh) 2017-08-29
CY1121185T1 (el) 2020-05-29
JP2015536318A (ja) 2015-12-21
US20160143968A1 (en) 2016-05-26
JP2018140999A (ja) 2018-09-13
CN105025931B (zh) 2017-04-05
KR20190067279A (ko) 2019-06-14
DK2908865T3 (en) 2019-01-28
KR20150068978A (ko) 2015-06-22
IL275874A (en) 2020-08-31
EP3441089B1 (en) 2022-12-14
US20150044280A1 (en) 2015-02-12
KR101989171B1 (ko) 2019-06-14
HRP20182125T1 (hr) 2019-02-08
EP3441089A1 (en) 2019-02-13
WO2014060848A3 (en) 2014-11-27
NZ707336A (en) 2019-01-25
AU2018271398B2 (en) 2020-11-05
AU2013333571B2 (en) 2017-01-19
AU2017202492B2 (en) 2018-09-06
IL238313B (en) 2020-07-30
EP2908865A2 (en) 2015-08-26
EA034163B1 (ru) 2020-01-13
US20220331383A1 (en) 2022-10-20
LT2908865T (lt) 2019-01-10
AU2017202492A1 (en) 2017-05-04
US20190054130A1 (en) 2019-02-21
MX2019007057A (es) 2019-08-29
SG10201706485WA (en) 2017-09-28
MX2015004835A (es) 2015-08-20
SG11201502941VA (en) 2015-05-28
US9200056B2 (en) 2015-12-01
JP6336459B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
HUE042262T2 (hu) FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
GB201120993D0 (en) Novel compounds and their use in therapy
HUE047912T2 (hu) Bilirubin részecskék és elõállításuk terápia során történõ alkalmazásra
DK3010519T3 (en) Oncolytic adenovirus for use in a treatment of brain cancer
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
GB201218084D0 (en) Novel compounds and methods for use in medicine
EP2896294A4 (en) MICRORNA IN HUMAN MILK AND USE THEREOF
EP2837319A4 (en) IN VIVO INTRODUCTION DEVICE AND ENDOSCOPE IN AN IN VIVO INTRODUCTION DEVICE
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
SG10201701165TA (en) Angiopoietin-like 4 antibody and a method of its use in cancer treatment
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB201308753D0 (en) Compounds and their use in therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201308217D0 (en) Compounds and their use in therapy
ZA201407164B (en) Device for use in the treatment hyperbilirubinemia
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201117876D0 (en) Peptides and their use in treatment
GB201312129D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB2498582B (en) Improvements in medical identity bracelets
GB201202945D0 (en) Novel cancer therapies and methods
AU2012903356A0 (en) Improvements in Medical Treatment
GB201019971D0 (en) Drug composition and its use in therapy